BMY - Bristol Myers to buy Karuna Therapeutics for $14B - WSJ
2023-12-22 06:52:51 ET
More on Karuna Therapeutics
- Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine
- Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript
- Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia
- AbbVie – Cerevel M&A deal lifts Reviva, Karuna
- FDA accepts Karuna Therapeutics schizophrenia drug for review
For further details see:
Bristol Myers to buy Karuna Therapeutics for $14B - WSJ